Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,225 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04145700 | CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma | terminated | Phase 1 / Phase 2 | 23 | Eli Lilly and CompanyINDUSTRY | 10 | Sep 13, 2023 | clinicaltrials |
| NCT01346787 | Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients(CCD) | completed | Phase 2 | 58 | European Myeloma Network B.V.NETWORK | 2 | Sep 8, 2023 |
| NCT05600127 | Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer(CHASIT) | recruiting | Phase 2 | 64 | Erasmus Medical CenterOTHER | 1 | Sep 8, 2023 | clinicaltrials |
| NCT01164995 | Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer(M10MKO) | completed | Phase 2 | 24 | The Netherlands Cancer InstituteOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT06015854 | Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II(Vvax) | unknown | Phase 2 | 18 | University Medical Center GroningenOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT06003998 | Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab(INTERACT-II) | unknown | Phase 2 | 85 | Catharina Ziekenhuis EindhovenOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT02034110 | Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers | completed | Phase 2 | 206 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 21, 2023 | clinicaltrials |
| NCT01616238 | A Study for Older Adults With Acute Lymphoblastic Leukaemia(UKALL60+) | completed | Phase 2 | 126 | University College, LondonOTHER | 2 | Aug 16, 2023 | clinicaltrials |
| NCT05222516 | Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD | terminated | Phase 2 | 63 | OM Pharma SAINDUSTRY | 4 | Aug 8, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT05076942 | Groningen International Study on Sentinel Nodes in Vulvar Cancer-III(GROINSS-VIII) | recruiting | Phase 2 | 157 | University Medical Center GroningenOTHER | 2 | Aug 1, 2023 | clinicaltrials |
| NCT00743262 | Short-term Clinical Feasibility of the New Provox Vega 22.5 Voice Prosthesis | completed | Phase 1 / Phase 2 | 15 | Atos Medical ABINDUSTRY | 1 | Jul 25, 2023 | clinicaltrials |
| NCT03637764 | Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 107 | SanofiINDUSTRY | 8 | Jul 10, 2023 | clinicaltrials |
| NCT02365441 | A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)(ALT GIST) | unknown | Phase 2 | 78 | Australasian Gastro-Intestinal Trials GroupNETWORK | 10 | Jul 7, 2023 | clinicaltrials |
| NCT02935634 | A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer(FRACTION-GC) | completed | Phase 2 | 190 | Bristol-Myers SquibbINDUSTRY | 9 | Jun 9, 2023 | clinicaltrials |
| NCT03519256 | A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder(CheckMate 9UT) | terminated | Phase 2 | 142 | Bristol-Myers SquibbINDUSTRY | 15 | Jun 1, 2023 | clinicaltrials |
| NCT03705507 | International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia(SeluDex) | terminated | Phase 1 / Phase 2 | 12 | University of BirminghamOTHER | 3 | May 11, 2023 | clinicaltrials |
| NCT04291300 | Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients(LUPSA) | completed | Phase 2 | 12 | Radboud University Medical CenterOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT01698918 | Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer(BOLERO-4) | completed | Phase 2 | 202 | Novartis PharmaceuticalsINDUSTRY | 13 | May 3, 2023 | clinicaltrials |
| NCT02823574 | Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(CheckMate 714) | completed | Phase 2 | 425 | Bristol-Myers SquibbINDUSTRY | 21 | May 3, 2023 | clinicaltrials |
| NCT02751255 | Daratumumab in Combination With ATRA(DARA/ATRA) | completed | Phase 1 / Phase 2 | 60 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT03458221 | Signal TrAnsduction Pathway Activity Analysis in OVarian cancER(STAPOVER) | recruiting | Phase 2 / Phase 3 | 148 | Gynaecologisch Oncologisch Centrum ZuidOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT03849105 | 131I-IPA and Concurrent XRT in Recurrent GBM(IPAX-1) | completed | Phase 1 / Phase 2 | 10 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 3 | Apr 14, 2023 | clinicaltrials |
| NCT02754141 | An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab | completed | Phase 1 / Phase 2 | 235 | Bristol-Myers SquibbINDUSTRY | 7 | Apr 5, 2023 | clinicaltrials |
| NCT03406468 | Re-Induction After Initial Response With Immune Therapy With Radiotherapy in Lung Cancer | completed | Phase 2 | 36 | Maastricht Radiation OncologyOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT03785925 | A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer(PIVOT-10) | completed | Phase 2 | 192 | Nektar TherapeuticsINDUSTRY | 18 | Mar 28, 2023 | clinicaltrials |
| NCT02872701 | OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules | completed | Phase 2 | 100 | On Target Laboratories, LLCINDUSTRY | 2 | Mar 24, 2023 | clinicaltrials |
| NCT02659384 | Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer | completed | Phase 2 | 122 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Mar 14, 2023 | clinicaltrials |
| NCT05767879 | (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma | unknown | Phase 2 | 28 | Leiden University Medical CenterOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT02598960 | An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread. | completed | Phase 1 / Phase 2 | 295 | Bristol-Myers SquibbINDUSTRY | 10 | Mar 6, 2023 | clinicaltrials |
| NCT03787602 | Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma | unknown | Phase 1 / Phase 2 | 115 | Kartos Therapeutics, Inc.INDUSTRY | 10 | Mar 2, 2023 | clinicaltrials |
| NCT03312530 | A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 49 | Hoffmann-La RocheINDUSTRY | 9 | Feb 28, 2023 | clinicaltrials |
| NCT05686213 | ExeNTrO: Exercise During Neoadjuvant Chemoradiation Treatment to Improve Rectal and Esophageal Cancer Outcome - Pilot Trial(ExeNTrO) | unknown | Phase 2 | 39 | Radboud University Medical CenterOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04014530 | Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study(ATAPEMBRO) | recruiting | Phase 1 / Phase 2 | 47 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT01986348 | Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas(KING) | terminated | Phase 2 | 76 | Karyopharm Therapeutics IncINDUSTRY | 3 | Jan 26, 2023 | clinicaltrials |
| NCT02088541 | Selinexor (KPT-330) in Older Patients With Relapsed AML(SOPRA) | completed | Phase 2 | 317 | Karyopharm Therapeutics IncINDUSTRY | 11 | Jan 26, 2023 | clinicaltrials |
| NCT05553808 | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1 | completed | Phase 2 | 105 | GlaxoSmithKlineINDUSTRY | 12 | Jan 19, 2023 | clinicaltrials |
| NCT04123340 | Intraprocedural Assessment of Ablation Margins Using Computed Tomography Co-registration in Primary Liver Tumor Treatment With Percutaneous Ablation(IAMCOMPLETE) | completed | Phase 2 | 20 | Leiden University Medical CenterOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT01939665 | PANFIRE Study: Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma(PANFIRE) | completed | Phase 1 / Phase 2 | 50 | Amsterdam UMC, location VUmcOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT02082782 | Efficacy of Irreversible Electroporation (IRE) for Central Colorectal Liver Metastases(COLDFIRE-2) | completed | Phase 2 | 51 | Amsterdam UMC, location VUmcOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT03170882 | A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma | completed | Phase 2 | 122 | Millennium Pharmaceuticals, Inc.INDUSTRY | 18 | Dec 20, 2022 | clinicaltrials |
| NCT03873493 | A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia | completed | Phase 2 | 14 | AbbVieINDUSTRY | 9 | Dec 19, 2022 | clinicaltrials |
| NCT03853187 | Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer(Donan) | completed | Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT05641233 | Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy(FIBROPANC-1) | unknown | Phase 1 / Phase 2 | 33 | Erasmus Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT02414750 | Vemurafenib Plus Cobimetinib in Metastatic Melanoma(REPOSIT) | terminated | Phase 2 | 78 | Netherlands Working Group on Immunotherapy of OncologyOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT01597414 | Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1 | completed | Phase 2 | 80 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Nov 17, 2022 | clinicaltrials |
| NCT02257567 | A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma | completed | Phase 1 / Phase 2 | 331 | Hoffmann-La RocheINDUSTRY | 13 | Nov 14, 2022 | clinicaltrials |
| NCT03784599 | T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC(TRAEMOS) | terminated | Phase 2 | 28 | The Netherlands Cancer InstituteOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT03379844 | HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients | completed | Phase 2 | 30 | UMC UtrechtOTHER | 1 | Nov 8, 2022 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials